Divarasib clinical trials
Divarasib is named as an intervention in 10 current clinical trials in our USA, Poland, Canada, South Korea, UK, Spain, Italy, Brazil, Japan, Belgium, Taiwan, Australia, China, Germany, France, Mexico, Portugal, Netherlands, Denmark, Switzerland, Singapore, Israel, Ireland, Egypt, Sweden, Austria, Turkey and Norway registers. 6 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Hoffmann-La Roche (8). The most-studied condition is Non-Small Cell Lung Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial, 1 with a site in Ireland.
How Divarasib works
All drug targets →- Non-small cell lung carcinomaPhase 3
- Central nervous system cancerPhase 2
- Central nervous system neoplasmPhase 2
- Colorectal cancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095236, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11963, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Divarasib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Divarasib
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Divarasib in the EU trials register (CTIS)
1 trial · 1 in IrelandAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Divarasib. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER
2025-524263-21-01 · Neoplasms
|
Phase 3 | Ongoing | F. Hoffmann-La Roche AG | Ireland + 10 more |
Conditions studied with Divarasib
8 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 8 |
| Genentech, Inc | 2 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Divarasib trials
How many clinical trials are testing Divarasib?
10 current trials in our USA, Poland, Canada, South Korea, UK, Spain, Italy, Brazil, Japan, Belgium, Taiwan, Australia, China, Germany, France, Mexico, Portugal, Netherlands, Denmark, Switzerland, Singapore, Israel, Ireland, Egypt, Sweden, Austria, Turkey and Norway registers name Divarasib (also registered as RO743584) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Divarasib trials recruiting patients?
Yes. 6 of the 10 trials are recruiting: 5 with sites in USA, 5 with sites in Poland, 5 with sites in Canada, 5 with sites in South Korea, 5 with sites in UK, 4 with sites in Spain, 4 with sites in Italy, 3 with sites in Brazil, 4 with sites in Japan, 3 with sites in Belgium, 4 with sites in Taiwan, 3 with sites in Australia, 4 with sites in China, 3 with sites in Germany, 2 with sites in France, 2 with sites in Mexico, 2 with sites in Portugal, 2 with sites in Netherlands, 2 with sites in Denmark, 2 with sites in Switzerland, 1 with sites in Singapore, 1 with sites in Israel, 2 with sites in Ireland, 1 with sites in Egypt and 1 with sites in Sweden. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Divarasib clinical trials?
Hoffmann-La Roche (8) and Genentech, Inc (2). The number in brackets is how many trials each organisation leads.
Are there Divarasib clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Divarasib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Divarasib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Divarasib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.